Currently out of the existing stock ratings of James Condulis, 19 are a BUY (90.48%), 2 are a HOLD (9.52%).

James Condulis

Work Performance Price Targets & Ratings Chart

Analyst James Condulis, currently employed at STIFEL, carries an average stock price target met ratio of 48.33% that have a potential upside of 46.01% achieved within 134 days.

James Condulis’s has documented 42 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MIRM, Mirum Pharmaceuticals at 29-Apr-2026.

Wall Street Analyst James Condulis

Analyst best performing recommendations are on EWTX (EDGEWISE THERAPEUTICS).
The best stock recommendation documented was for SLNO (SOLENO THERAPEUTICS) at 3/12/2025. The price target of $74 was fulfilled within 43 days with a profit of $27.3 (58.46%) receiving and performance score of 13.59.

Average potential price target upside

of $41.75 (111.94%) on CYTK (CYTOKINETICS).
of $28.16 (61.47%) on SLNO (SOLENO THERAPEUTICS).
of $27.04 (40.64%) on MIRM (MIRUM PHARMACEUTICALS).

CYTK Cytokinetics EWTX Edgewise Therapeutics MIRM Mirum Pharmaceuticals NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares SLNO Soleno Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Tessa Romero (JPMORGAN)